[DISCLOSURE] ViroMed (084990) announced on Aug. 1 that its VM202RY has been approved to initiate phase 2 of its clinical trials. VM202RY is a medicine for acute myocardial infarction by directly injecting into the cardiac muscles of the coronary artery territory.